Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
5.26
+0.01 (0.19%)
Jul 11, 2025, 4:00 PM - Market closed
Rezolute Employees
Rezolute had 59 employees as of June 30, 2024. The number of employees increased by 8 or 15.69% compared to the previous year.
Employees
59
Change (1Y)
8
Growth (1Y)
15.69%
Revenue / Employee
n/a
Profits / Employee
-$1,237,254
Market Cap
449.83M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RZLT News
- 2 days ago - Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) - GlobeNewsWire
- 6 weeks ago - Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism - GlobeNewsWire
- 2 months ago - Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - GlobeNewsWire
- 2 months ago - Rezolute to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Rezolute: RZ402 Could Be A Surprise Candidate In The Making - Seeking Alpha
- 2 months ago - Rezolute, Inc. Announces Closing of Underwritten Offering - GlobeNewsWire
- 2 months ago - Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December - Benzinga